vs

Side-by-side financial comparison of ChargePoint Holdings, Inc. (CHPT) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

ChargePoint Holdings, Inc. is the larger business by last-quarter revenue ($105.7M vs $74.7M, roughly 1.4× Health Catalyst, Inc.). ChargePoint Holdings, Inc. runs the higher net margin — -49.7% vs -121.9%, a 72.2% gap on every dollar of revenue. On growth, ChargePoint Holdings, Inc. posted the faster year-over-year revenue change (6.1% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-23.6M). Over the past eight quarters, Health Catalyst, Inc.'s revenue compounded faster (-0.0% CAGR vs -4.5%).

ChargePoint Holdings, Inc. is an American electric vehicle infrastructure company based in Campbell, California. ChargePoint operates the largest online network of independently owned EV charging stations operating in 14 countries and makes some of its technology.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

CHPT vs HCAT — Head-to-Head

Bigger by revenue
CHPT
CHPT
1.4× larger
CHPT
$105.7M
$74.7M
HCAT
Growing faster (revenue YoY)
CHPT
CHPT
+12.3% gap
CHPT
6.1%
-6.2%
HCAT
Higher net margin
CHPT
CHPT
72.2% more per $
CHPT
-49.7%
-121.9%
HCAT
More free cash flow
HCAT
HCAT
$33.2M more FCF
HCAT
$9.6M
$-23.6M
CHPT
Faster 2-yr revenue CAGR
HCAT
HCAT
Annualised
HCAT
-0.0%
-4.5%
CHPT

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CHPT
CHPT
HCAT
HCAT
Revenue
$105.7M
$74.7M
Net Profit
$-52.5M
$-91.0M
Gross Margin
30.7%
Operating Margin
-42.0%
-115.3%
Net Margin
-49.7%
-121.9%
Revenue YoY
6.1%
-6.2%
Net Profit YoY
32.4%
-340.3%
EPS (diluted)
$-2.23
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHPT
CHPT
HCAT
HCAT
Q4 25
$105.7M
$74.7M
Q3 25
$98.6M
$76.3M
Q2 25
$97.6M
$80.7M
Q1 25
$101.9M
$79.4M
Q4 24
$99.6M
$79.6M
Q3 24
$108.5M
$76.4M
Q2 24
$107.0M
$75.9M
Q1 24
$115.8M
$74.7M
Net Profit
CHPT
CHPT
HCAT
HCAT
Q4 25
$-52.5M
$-91.0M
Q3 25
$-66.2M
$-22.2M
Q2 25
$-57.1M
$-41.0M
Q1 25
$-58.8M
$-23.7M
Q4 24
$-77.6M
$-20.7M
Q3 24
$-68.9M
$-14.7M
Q2 24
$-71.8M
$-13.5M
Q1 24
$-94.7M
$-20.6M
Gross Margin
CHPT
CHPT
HCAT
HCAT
Q4 25
30.7%
Q3 25
31.2%
52.6%
Q2 25
28.7%
Q1 25
28.2%
Q4 24
22.9%
Q3 24
23.6%
47.5%
Q2 24
22.1%
Q1 24
19.3%
Operating Margin
CHPT
CHPT
HCAT
HCAT
Q4 25
-42.0%
-115.3%
Q3 25
-59.8%
-22.9%
Q2 25
-55.1%
-46.0%
Q1 25
-53.9%
-25.4%
Q4 24
-68.4%
-22.0%
Q3 24
-57.8%
-17.9%
Q2 24
-62.7%
-20.8%
Q1 24
-80.2%
-30.5%
Net Margin
CHPT
CHPT
HCAT
HCAT
Q4 25
-49.7%
-121.9%
Q3 25
-67.1%
-29.1%
Q2 25
-58.5%
-50.8%
Q1 25
-57.7%
-29.9%
Q4 24
-77.9%
-26.0%
Q3 24
-63.5%
-19.3%
Q2 24
-67.1%
-17.8%
Q1 24
-81.8%
-27.6%
EPS (diluted)
CHPT
CHPT
HCAT
HCAT
Q4 25
$-2.23
$-1.29
Q3 25
$-2.85
$-0.32
Q2 25
$-0.12
$-0.59
Q1 25
$-5.83
$-0.35
Q4 24
$-3.56
$-0.33
Q3 24
$-3.22
$-0.24
Q2 24
$-0.17
$-0.23
Q1 24
$-23.36
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHPT
CHPT
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$180.5M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$38.4M
$245.8M
Total Assets
$848.0M
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHPT
CHPT
HCAT
HCAT
Q4 25
$180.5M
$95.7M
Q3 25
$194.1M
$91.5M
Q2 25
$195.9M
$97.3M
Q1 25
$224.6M
$342.0M
Q4 24
$219.4M
$392.0M
Q3 24
$243.3M
$387.3M
Q2 24
$261.9M
$308.3M
Q1 24
$327.4M
$327.8M
Total Debt
CHPT
CHPT
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
CHPT
CHPT
HCAT
HCAT
Q4 25
$38.4M
$245.8M
Q3 25
$70.7M
$331.9M
Q2 25
$118.6M
$347.5M
Q1 25
$137.5M
$376.8M
Q4 24
$181.0M
$365.2M
Q3 24
$230.9M
$355.0M
Q2 24
$277.9M
$357.0M
Q1 24
$327.7M
$357.2M
Total Assets
CHPT
CHPT
HCAT
HCAT
Q4 25
$848.0M
$502.6M
Q3 25
$870.3M
$587.1M
Q2 25
$897.6M
$616.2M
Q1 25
$898.2M
$891.5M
Q4 24
$966.3M
$858.9M
Q3 24
$1.0B
$813.0M
Q2 24
$1.1B
$691.7M
Q1 24
$1.1B
$695.1M
Debt / Equity
CHPT
CHPT
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHPT
CHPT
HCAT
HCAT
Operating Cash FlowLast quarter
$-22.5M
$9.9M
Free Cash FlowOCF − Capex
$-23.6M
$9.6M
FCF MarginFCF / Revenue
-22.3%
12.9%
Capex IntensityCapex / Revenue
1.0%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.6M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHPT
CHPT
HCAT
HCAT
Q4 25
$-22.5M
$9.9M
Q3 25
$-6.2M
$-464.0K
Q2 25
$-33.0M
$-9.0M
Q1 25
$-2.7M
$280.0K
Q4 24
$-30.6M
$-3.5M
Q3 24
$-51.2M
$6.2M
Q2 24
$-62.5M
$1.6M
Q1 24
$-41.5M
$10.3M
Free Cash Flow
CHPT
CHPT
HCAT
HCAT
Q4 25
$-23.6M
$9.6M
Q3 25
$-7.5M
$-719.0K
Q2 25
$-34.0M
$-9.2M
Q1 25
$-4.6M
$-390.0K
Q4 24
$-33.4M
$-3.9M
Q3 24
$-55.0M
$5.5M
Q2 24
$-66.0M
$1.3M
Q1 24
$-46.2M
$10.1M
FCF Margin
CHPT
CHPT
HCAT
HCAT
Q4 25
-22.3%
12.9%
Q3 25
-7.6%
-0.9%
Q2 25
-34.9%
-11.4%
Q1 25
-4.5%
-0.5%
Q4 24
-33.5%
-4.9%
Q3 24
-50.7%
7.2%
Q2 24
-61.7%
1.7%
Q1 24
-39.9%
13.5%
Capex Intensity
CHPT
CHPT
HCAT
HCAT
Q4 25
1.0%
0.4%
Q3 25
1.3%
0.3%
Q2 25
1.1%
0.3%
Q1 25
1.9%
0.8%
Q4 24
2.8%
0.5%
Q3 24
3.5%
0.9%
Q2 24
3.2%
0.4%
Q1 24
4.1%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHPT
CHPT

Products$56.4M53%
License And Service$42.0M40%
Other$7.3M7%

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons